Wu Nan, Chen Qiuting, Zou Yongjuan, Miao Chunyu, Ma Guanghui, Wu Jie
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou 510006, PR China.
Carbohydr Polym. 2023 Jun 1;309:120673. doi: 10.1016/j.carbpol.2023.120673. Epub 2023 Feb 6.
Particle-emulsion complex adjuvants as a new trend in the research of vaccine formulation, can improve the immune strength and balance the immune type. However, the location of the particle in the formulation is a key factor that has not been investigated extensively and its type of immunity. In order to investigate the effect of different combining modes of emulsion and particle on the immune response, three types of particle-emulsion complex adjuvant formulations were designed with the combination of chitosan nanoparticles (CNP) and an o/w emulsion with squalene as the oil phase. The complex adjuvants included the CNP-I group (particle inside the emulsion droplet), CNP-S group (particle on the surface of emulsion droplet) and CNP-O group (particle outside the emulsion droplet), respectively. The formulations with different particle locations behaved with different immunoprotective effects and immune-enhancing mechanisms. Compared with CNP-O, CNP-I and CNP-S significantly improve humoral and cellular immunity. CNP-O was more like two independent systems for immune enhancement. As a result, CNP-S triggered a Th1-type immune bias and CNP-I had more of a Th2-type of the immune response. These data highlight the key influence of the subtle difference of particle location in the droplets for immune response.
颗粒-乳液复合佐剂作为疫苗制剂研究的新趋势，可提高免疫强度并平衡免疫类型。然而，颗粒在制剂中的位置是一个尚未得到广泛研究的关键因素及其免疫类型。为了研究乳液与颗粒的不同组合方式对免疫反应的影响，设计了三种类型的颗粒-乳液复合佐剂制剂，将壳聚糖纳米颗粒（CNP）与以角鲨烯为油相的o/w乳液相结合。复合佐剂分别包括CNP-I组（颗粒在乳液滴内部）、CNP-S组（颗粒在乳液滴表面）和CNP-O组（颗粒在乳液滴外部）。具有不同颗粒位置的制剂表现出不同的免疫保护作用和免疫增强机制。与CNP-O相比，CNP-I和CNP-S显著提高体液免疫和细胞免疫。CNP-O更像是两个独立的免疫增强系统。结果，CNP-S引发Th1型免疫偏向，而CNP-I更多地引发Th2型免疫反应。这些数据突出了颗粒在液滴中位置的细微差异对免疫反应的关键影响。
